eTheRNA Immunotherapies NV:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:eTheRNA Immunotherapies NV - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11035
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:21
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ベルギー
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
ETheRNA Immunotherapies NV (eTheRNA) is a developer of novel immunotherapies for the treatment of cancers and infectious diseases. The company’s pipeline products include mRNA-based immunotherapies for various indications such as melanoma, triple negative breast cancer and infectious diseases. It provides preclinical and clinical proof to support further development of TriMix technology. eTheRNA also develops drugs for infectious diseases such as influenza, pneumonia, tuberculosis, Lyme disease, HIV and AIDS et cetera. The company also provides contract manufacturing services. It has collaborative partnerships with pharma companies for its research operations. eTheRNA is headquartered in Antwerp, Belgium.

eTheRNA Immunotherapies NV – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
eTheRNA Immunotherapies NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
eTheRNA Immunotherapies NV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
eTheRNA Immunotherapies NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
eTheRNA Immunotherapies NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
eTheRNA Immunotherapies NV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
eTheRNA Immunotherapies NV, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
eTheRNA Raises USD27 Million in Series A Financing 10
Partnerships 12
Mymetics Enters into Research Collaboration Agreement with eTheRNA 12
PCI Biotech Enters Research Agreement with eTheRNA immunotherapies 13
Licensing Agreements 14
eTheRNA Enters into Licensing Agreement with Vrije Universiteit Brussel 14
eTheRNA Immunotherapies NV – Key Competitors 15
eTheRNA Immunotherapies NV – Key Employees 16
eTheRNA Immunotherapies NV – Locations And Subsidiaries 17
Head Office 17
Other Locations & Subsidiaries 17
Recent Developments 18
Government and Public Interest 18
Sep 25, 2017: eTheRNA immunotherapies Awarded €1 Million Grant From Flanders Innovation & Entrepreneurship to Further Upgrade its State-of-the-art Production Process for TriMix mRNA Immunotherapies 18
Clinical Trials 19
Mar 19, 2018: eTheRNA completes enrolment of low dose cohort for Phase 1b study of TriMix mRNA-based cancer specific immunotherapy (ECI-006) in melanoma 19
Jun 30, 2017: etherna Advances in-vivo MRNA Cancer Immunotherapy Into First Oncology Clinical Studies 20
Appendix 21
Methodology 21
About GlobalData 21
Contact Us 21
Disclaimer 21

List of Tables
eTheRNA Immunotherapies NV, Pharmaceuticals & Healthcare, Key Facts 2
eTheRNA Immunotherapies NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
eTheRNA Immunotherapies NV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
eTheRNA Immunotherapies NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
eTheRNA Immunotherapies NV, Deals By Therapy Area, 2012 to YTD 2018 8
eTheRNA Immunotherapies NV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
eTheRNA Raises USD27 Million in Series A Financing 10
Mymetics Enters into Research Collaboration Agreement with eTheRNA 12
PCI Biotech Enters Research Agreement with eTheRNA immunotherapies 13
eTheRNA Enters into Licensing Agreement with Vrije Universiteit Brussel 14
eTheRNA Immunotherapies NV, Key Competitors 15
eTheRNA Immunotherapies NV, Key Employees 16
eTheRNA Immunotherapies NV, Other Locations 17

List of Figures
eTheRNA Immunotherapies NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
eTheRNA Immunotherapies NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
eTheRNA Immunotherapies NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
eTheRNA Immunotherapies NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
eTheRNA Immunotherapies NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
eTheRNA Immunotherapies NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
eTheRNA Immunotherapies NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
eTheRNA Immunotherapies NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[eTheRNA Immunotherapies NV:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Scomi Group Bhd (SCOMI):企業の財務・戦略的SWOT分析
    Scomi Group Bhd (SCOMI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Diversicare Healthcare Services Inc (DVCR):製薬・医療:M&Aディール及び事業提携情報
    Summary Diversicare Healthcare Services Inc (Diversicare), formerly Advocat Inc is a healthcare service provider that offers post acute care services and short term rehabilitation and long-term care services to nursing home patients. The company’s services include life steps rehabilitation program, …
  • Chongqing Lummy Pharmaceutical Co Ltd (300006):製薬・医療:M&Aディール及び事業提携情報
    Summary Chongqing Lummy Pharmaceutical Co Ltd (Lummy) is a pharmaceutical company that provides pharmaceutical ingredients and drugs and related products. The company’s products include antibacterial drugs, antifungal drugs, tumor drugs, immune system agents, blood system agents, cardiovascular syst …
  • Plexxikon Inc-製薬・医療分野:企業M&A・提携分析
    Summary Plexxikon Inc (Plexxikon), a subsidiary of Daiichi Sankyo Company Ltd is a drug discovery company that concentrates on discovery and development of novel, small molecules. The company’s pipeline products include PLX3397 to treat adjuvant glioblastoma, neoadjuvant breast, melanoma and solid t …
  • Showa Denko K.K.:企業の戦略・SWOT・財務分析
    Showa Denko K.K. - Strategy, SWOT and Corporate Finance Report Summary Showa Denko K.K. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Bioactive Bone Substitutes Plc (BONEH):企業の製品パイプライン分析
    Summary Bioactive Bone Substitutes Plc (BBS) is a health technology company that manufactures biologically active medical device implants for orthopedic surgery. The company provides technology platforms, artebone, research and development, patents, and others. It offers artebone which is made up of …
  • Fingrid Oyj:企業の戦略的SWOT分析
    Fingrid Oyj - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • The Coca-Cola Co:戦略・SWOT・企業財務分析
    The Coca-Cola Co - Strategy, SWOT and Corporate Finance Report Summary The Coca-Cola Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Medical Developments International Ltd (MVP):企業の財務・戦略的SWOT分析
    Summary Medical Developments International Ltd (MDI) is a healthcare company that develops, manufactures and markets pain relief and respiratory medicine. The company provides products such as penthrox, asthma and COPD, medical devices and veterinary products. It offers asthma and COPD products whic …
  • Coslight Technology International Group Ltd (1043):企業の財務・戦略的SWOT分析
    Coslight Technology International Group Ltd (1043) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key …
  • Epsilon Energy Ltd (EPS):石油・ガス:M&Aディール及び事業提携情報
    Summary Epsilon Energy Ltd (Epsilon) is an oil and gas company that provides exploration, exploitation and development of oil and gas reserves. The company provides projects such as Marcellus shale in northeast Pennsylvania, Bakken Shale and Midale Dolomite in Saskatchewan, among others. It operates …
  • Ingredia Nutritional:企業の戦略・SWOT・財務情報
    Ingredia Nutritional - Strategy, SWOT and Corporate Finance Report Summary Ingredia Nutritional - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Aptiv Plc. (APTV):企業の財務・戦略的SWOT分析
    Aptiv Plc. (APTV) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • AEON Credit Service (M) Berhad:企業の戦略・SWOT・財務情報
    AEON Credit Service (M) Berhad - Strategy, SWOT and Corporate Finance Report Summary AEON Credit Service (M) Berhad - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Generali France S.A.:企業の戦略・SWOT・財務分析
    Generali France S.A. - Strategy, SWOT and Corporate Finance Report Summary Generali France S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • N V Nederlandse Gasunie:企業の戦略・SWOT・財務情報
    N V Nederlandse Gasunie - Strategy, SWOT and Corporate Finance Report Summary N V Nederlandse Gasunie - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Argenx SE (ARGX):企業の財務・戦略的SWOT分析
    Summary Argenx SE (Argenx) is a human antibodies developer. The company offers autoimmunity and oncology products. Its wholly owned product candidates include ARGX-113, ARGX-110, ARGX-117 and ARGX-111. Argenx partnered product candidates are ARGX-109, ARGX-112, ARGX-115 AND ARGX-116. The company off …
  • Obrascon Huarte Lain SA:戦略・SWOT・企業財務分析
    Obrascon Huarte Lain SA - Strategy, SWOT and Corporate Finance Report Summary Obrascon Huarte Lain SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Hexion Inc.:企業の戦略・SWOT・財務情報
    Hexion Inc. - Strategy, SWOT and Corporate Finance Report Summary Hexion Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • ALTANA AG:戦略・SWOT・企業財務分析
    ALTANA AG - Strategy, SWOT and Corporate Finance Report Summary ALTANA AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆